This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Dan DeNeui Named COO Of BioTE Medical

DALLAS, Jan. 24, 2013 /PRNewswire/ -- BioTE Medical founder and President Dr. Gary Donovitz today announced the promotion of Dan DeNeui to COO.    BioTE Medical is a Texas-based company that has played a significant role in the development of subcutaneous testosterone pellet therapy for men and women.  DeNeui had been serving as the company's Vice President-Business Development.   

(Photo:  http://photos.prnewswire.com/prnh/20130124/LA48054)

Commenting on the promotion of DeNeui, Dr. Donovitz said, " Dan DeNeui has been such a critical part of our success at BioTE Medical.   He was been instrumental in the launching of our company several years ago and is a major reason that BioTE is emerging as a national leader in the field of safe and effective testosterone replacement for men and women."  According to Donovitz, DeNeui led an expansion of BioTE Medical to new markets.  Donovitz added, "Because of Dan and our team, the BioTE Method of safe and effective testosterone pellet therapy is now being offered by leading medical professionals in a number of markets in the US.  With the momentum that's been built, BioTE testosterone pellet therapy will be available coast to coast in the next year." 

Dan DeNeui stated, "It's been a privilege to work with Dr. Donovitz, my staff and the medical practitioners who offer the BioTE Method.   It's been very exciting to see our growth over the past 3 years.   It is evident that BioTE is on the verge of some very exciting times ahead. We currently boast the largest patient population receiving the exact same Bio Identical Hormone Replacement Therapy in the US, and that number is growing exponentially each year.  This obviously provides our company with some incredible opportunities."

In a marketplace that is becoming increasingly competitive with testosterone replacement creams, gels and shots, DeNeui said that the BioTE Method is being enthusiastically received by both consumers and physicians.   DeNeui added, "There are numerous products on the market that simply don't work efficiently.  And there are others, such as synthetic testosterone shots, that can present major issues for consumers.  At BioTE Medical, we're driven by excellence.  Bio-identical testosterone pellet therapy is by far the best method for both men and women to safely balance their hormones.   And as trained medical professionals compare other modalities with BioTE Medical's testosterone pellets, we have become the best practices standard." 

Dr. Donovitz praised the quality of physicians and medical practitioners who have joined team of professionals offering the BioTE Method.   Donovitz stated, "We've been able to align ourselves with the best physicians and medical professionals in all of our markets.    Compared to other clinics offering hormone replacement therapy, our physicians are clearly the most knowledgeable, best trained and most successful." 

Both Donovitz and DeNeui cited BioTE Medical's physician training as a point of differentiation.   DeNeui added, "When BioTE Medical partners with a doctor, we start with very complete training for not only the doctor but also their key employees.  And it doesn't stop there.   We're very committed to ongoing dialog and support.  In fact, we have a division of the company that offers marketing support for our partners." 

Regarding the growth of BioTE Medical, both Dr. Donovitz and DeNeui agree that the company is on the verge of significant growth.  Dr. Donovitz added, "We're positioned well for major growth this year and beyond.   Dan's done an exemplary job of building the infrastructure.   The future is, indeed, very bright." 

Interviews Available

Contact: Pete Thomson McQ Media214-257-8484

SOURCE BioTE Medical

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,067.61 +37.40 0.21%
S&P 500 2,090.50 +8.62 0.41%
NASDAQ 4,799.8510 +26.3790 0.55%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs